Search

everythinglearnresearchcommunity

for

Search:↓

The post discusses the impact of Ashwagandha on hair loss, highlighting its ability to lower stress levels, which is beneficial for hair health. However, there's uncertainty about its potential to increase testosterone and DHT, which could contribute to hair loss.

The user reported progress in hair growth after 7 months using dutasteride, oral minoxidil (2.5 mg once daily), and Nizoral, noting improvements in hair thickness and density. The user experienced no side effects and plans to continue the treatment.

The conversation is about sourcing Winlevi (clascoterone) for personal use in the EU. The user is specifically looking for a non-generic version.

The user plans to use a 1.5 mm dermapen for microneedling every 10 days and is considering applying aloe vera afterward. They also inquire about the timing for washing their hair before and after the treatment.

The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.

A user started taking Dutasteride and experienced significant shedding initially, but it has since stopped after three months. They noticed some changes but are unsure if they are solely due to Dutasteride.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

Topical ashwagandha is discussed as a potential hair loss treatment. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

The user is experiencing stage 2 hair loss and thinning, noticing more scalp visibility with short hair. They are considering diet, yoga, scalp massage, supplements, and a serum recommended by their doctor, and questioning if it's safe to stop using the serum and whether to get a blood test since hair loss isn't a family trait.

A woman with alopecia universalis shares her positive experience of being bald, finding it freeing and less worrisome. She also discusses her skincare routine using Korean products.

User experienced severe brain fog and anxiety from oral dutasteride and is considering dutasteride injections with PRP for hair loss, while currently using finasteride and oral minoxidil. They seek others' experiences with dutasteride mesotherapy and its side effects.

The conversation humorously discusses George Clooney's hair and aging, suggesting he switch to dutasteride for his temples. It also mentions minoxidil and finasteride, debating the effects of hair dye and styling on his appearance.

The user has been on dutasteride for 6 months, experiencing initial hair health but then shedding and brittle hair, with no improvement. They use minoxidil, ketoconazole, dutasteride, and vitamin D, and are questioning whether to continue treatment despite no results.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

Annual hair shedding occurs for user, lasting 3 months, despite various factors. User takes Finasteride, Minoxidil, and Dutasteride, and experiences regrowth but fears weakening hairline.

A person feels intense shame and self-hatred due to baldness and poor self-image, affecting their confidence and social interactions. Suggestions include therapy, exercise, braces, hair transplants, and using finasteride.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

User reports worsening hair loss despite using Avodart 0.5mg daily and 2ml of Minoxidil daily for over three years. They maintain a healthy lifestyle and are athletic.

The conversation discusses using Morr F Aqua, an alcohol-free version of Minoxidil, for hair loss, particularly for someone with dandruff issues. The user is considering if this product is suitable for their condition.

There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.

Dutasteride can be obtained through Amazon for $13.60 a month with Prime, and some users prefer it over finasteride due to its effectiveness and similar side effects. Finasteride is also available for $16 for a 3-month supply, and some users report no side effects, while others experience issues like tenderness and swelling.

Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.

The conversation humorously discusses using anal administration of Dutasteride as a novel method for treating hair loss, suggesting it could target DHT production more effectively. It includes satirical comments about the method's potential effects and absurd outcomes.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

The user shared their experience with dutasteride for hair loss prevention, noting side effects like muscle weakness and brain fog, and observed increased testosterone levels. They recommend starting with a low dose and adjusting based on individual needs and blood work results.

The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.

Taking 2.5mg of dutasteride daily can cause feelings of low energy, ambition, and motivation, likely due to hormonal imbalances. Many users suggest lowering the dose to 0.5mg to alleviate these side effects.